<DOC>
	<DOCNO>NCT01421173</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose vorinostat give gemcitabine , busulfan , melphalan stem cell transplant . Researchers also want learn safety level effectiveness combination . Busulfan melphalan design kill cancer cell bind DNA ( genetic material cell ) , may cause cancer cell die . Gemcitabine design disrupt growth cancer cell , may cause cancer cell die . It may help increase effect busulfan melphalan cancer cell allow cell repair DNA damage cause busulfan melphalan . Vorinostat design open DNA allow great access drug bind DNA , gemcitabine , busulfan melphalan .</brief_summary>
	<brief_title>Vorinostat With Gemcitabine , Busulfan , Melphalan With Stem Cell Transplant ( SCT ) Relapsed Refractory Lymphoid Malignancies</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , enrol group least 3 participant begin receive study drug . The dose study drug receive depend enrol study . If intolerable side effect occur group , researcher continue enroll participant next dose level either vorinostat reach dose level currently use alone without stem cell transplant , high tolerable dose drug find . The dose receive remain throughout study . Busulfan Test Dose : You receive test dose busulfan vein 60 minute . This low-level test dose busulfan check level busulfan blood level change time . This information use decide next dose need reach target blood level match body size . You likely receive outpatient week admit hospital . If give outpatient , admitted hospital Day -11 ( 11 day stem cell return body ) test dose give Day -10 . About 11 sample blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test busulfan . PK test measure amount study drug body different time point help study doctor determine dose busulfan study . These blood sample draw various timepoints receive busulfan next 11 hour . The blood sample repeat first day high-dose busulfan treatment ( Day -8 ) . A temporary heparin lock line place vein low number needle stick need draws . If possible PK test perform technical scheduling reason , receive standard fix dose busulfan . If receive busulfan test dose outpatient : On Days -12 , -11 , -10 , receive palifermin vein 30 second day help decrease risk side effect mouth throat . You admitted hospital Day -9 . If receive busulfan test dose inpatient : On Days -13 , -12 , -11 , receive palifermin vein 30 second day help decrease risk side effect mouth throat . You admitted hospital Day -11 . Study Drug Administration ( patient ) : In stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . Beginning Day -9 , swish liquid caphosol glutamine mouth 4 time day , 2 minute time . You swish liquid every day leave hospital . These drug use help decrease risk side effect mouth throat . On Day -8 Day -2 , take vorinostat mouth , food . On Day -8 , receive gemcitabine vein 3 1/2 - 4 1/2 hour busulfan vein 3 hour . On Days -8 , -7 , -6 , -5 , receive busulfan vein 3 hour . On Day -3 , receive gemcitabine vein 3 1/2 - 4 1/2 hour melphalan vein 30 minute . On Day -2 , receive melphalan vein 30 minute . On Day -1 , rest . On Day 0 , receive stem cell vein 30-60 minute . You receive 3 dos palifermin vein 15-30 second Days 0 , +1 +2 . If B-cell cancer , receive rituximab ( treatment use certain lymphomas chronic lymphocytic leukemia ) vein 3-6 hour part standard care , Days +1 +8 . As part standard care , receive G-CSF ( filgrastim ) injection skin 1 time day start Day +5 blood cell level return normal . Study Tests : On Day -1 , electrocardiogram ( ECG ) check heart function . About 30-100 day transplant , lung function test . About 100 day transplant : - Blood ( 4 teaspoon ) draw routine test . - If doctor think need , may bone marrow aspiration biopsy check status disease . - You CT scan neck , chest , abdomen , pelvis check status disease . - If doctor think need , PET scan check status disease . Length Study : As part standard care , remain hospital 3-4 week transplant . After release hospital , continue outpatient Houston area monitor infection transplant-related complication . You take study 100 day transplant . You may take study early disease get bad , intolerable side effect occur , unable follow study direction . This investigational study . Vorinostat , gemcitabine , busulfan , melphalan , rituximab FDA approve commercially available . The use study drug combination investigational . Up 80 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>1 . Age 12 65 year 2 . Patients primary refractory recurrent nonHodgkin 's lymphoma ( NHL ) HL qualify treatment protocol high priority . 3 . Patients doublehit NHL , state disease . 4 . Patients peripheral Tcell lymphoma otherwise specify ( PTCLNOS ) state disease . 5 . Angioimmunoblastic Tcell lymphoma ( AITL ) stage disease . 6 . Adequate renal function , define estimate serum creatinine clearance &gt; /=50 ml/min and/or serum creatinine &lt; /= 1.8 mg/dL . 7 . Adequate hepatic function , define serum glutamate oxaloacetate transaminase ( SGOT ) and/or serum glutamate pyruvate transaminase ( SGPT ) &lt; /= 3 x upper limit normal ; serum bilirubin alkaline phosphatase &lt; /= 2 x upper limit normal . 8 . Adequate pulmonary function force expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) diffuse capacity lung carbon monoxide ( DLCO ) &gt; /= 50 % expect corrected hemoglobin . 9 . Adequate cardiac function leave ventricular ejection fraction &gt; /= 40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 10 . Zubrod performance status &lt; 2 . 11 . Negative Beta diffusing capacity lung carbon monoxide ( HCG ) text woman childbearing potential , define postmenopausal 12 month previous surgical sterilization 1 . Patients grade &gt; /= 3 nonhematologic toxicity previous therapy resolve &lt; /= grade 1 . 2 . Patients prior whole brain irradiation 3 . Patients active hepatitis B , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; /=10,000 copies/mL , &gt; /= 2,000 IU/mL ) . 4 . Evidence either cirrhosis stage 34 liver fibrosis patient chronic hepatitis C positive hepatitis C serology . 5 . Active infection require parenteral antibiotic 6 . HIV infection , unless patient receive effective antiretroviral therapy undetectable viral load normal cluster differentiation 4 ( CD4 ) count 7 . Patients receive radiation therapy month prior enrollment . 8 . Patients cQT longer 500 m</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoid malignancy</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Autologous hematopoietic cell support</keyword>
	<keyword>Stem cell infusion</keyword>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>SAHA</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
	<keyword>Zolinza</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>NeupogenTM</keyword>
	<keyword>Palifermin</keyword>
	<keyword>Kepivance</keyword>
</DOC>